Could Buying This Dividend Pharma Stock Today Set You Up for Life?

Johnson & Johnson has increased its dividend for more than 60 consecutive years, highlighting a durable capital-return profile. The company’s diversification beyond pharmaceuticals into other businesses offers additional growth avenues and greater business stability, supporting the longevity of the dividend.

Analysis

Johnson & Johnson has increased its dividend for more than 60 consecutive years, highlighting a durable capital-return profile. The company’s diversification beyond pharmaceuticals into other businesses offers additional growth avenues and greater business stability, supporting the longevity of the dividend.